Fatal outcome of disseminated candidosis after allogeneic bone marrow transplantation under treatment with liposomal and conventional amphotericin-B. A report of 4 cases with determination of the MIC values

Scandinavian Journal of Infectious Diseases

Volumn 28, Issue 3, 1996, Pages 313-316

  Kruger W ^a   Sobottka, I ^a   Stockschlader M ^a   Mross, K ^b   Hoffknecht, M ^a   Rußmann B ^a   Horstmann, M ^a   Betker, R ^a   Zander, A ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Center for Tumor Biology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; LIPOSOME;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDIASIS; CASE REPORT; FATALITY; FEMALE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE ORGAN FAILURE;

EID: 0029745101     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365549609027181     Document Type: Article

References (18)

1. Nosari A, Baberis M, Landonio G, Magnani P, Majno M, Oreste P, Sozzi P. Infections in haematologic neoplasms: autopsy findings. Haematologica 76: 135-140, 1991.
2. Pizzo PA, Rubin M, Freifeld A, Walsh TJ. Medical progress. The child with cancer and infection. I. Empiric therapy for fever and neutropenia, and preventive strategies. J Pediatr 5: 679-694, 1991.
3. Pizzo PA, Rubin M, Freifeld A, Walsh TJ. Medical progress. The child with cancer and infection. II. Nonbacterial infections. J Pediatr 6: 845-857, 1991.
4. Butler WT, Bennett JE, Elling DW, Wertlake PT, Utz JP, Hill GJ. Nephrotoxicity of amphotericin-B - Early and late effects in 81 patients. Ann Intern Med 2: 175-187, 1994.
5. Meyer RD. Current role of therapy with amphotericin-B. Clin Infect Dis 14 (Suppl 1): 154-160, 1992.
6. Emminger W, Graninger W, Emminger-Schmidtmeier W, Zoubek K, Pillwein K, Susani M, Wasserer A, Gadner H. Tolerance of high doses of amphotericin-B by infusion of a liposomal formulation in children with cancer. Ann Hematol 68: 27-31, 1994.
7. Mills W, Chopra R, Linch DC, Goldstone AH. Liposomal amphotericin-B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br J Haematol 86: 754-760, 1994.
8. Anaissie E, Paetznick V, Proffitt R, Adler-Moore J, Bodey GP. Comparison of the in vitro antifungal activity of free and liposome encapsulated amphotericin-B. Eur J Clin Microbiol Infect Dis 10: 665-668, 1991.
9. Hopfer RL, Mills K, Mehta R, Lopez-Berenstein G, Fainstein V, Juliano RL. In vitro antifungal activities of amphotericin-B and liposome-encapsulated amphotericin-B. Antimicrob Agents Chemother 25: 387-389, 1984.
10. Fielding RM, Singer AW, Wang LH, Babbar S, Guo LSS. Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin-B colloidal dispersion in dogs. Antimicrob Agents Chemother 36: 299-307, 1992.
11. Coker R, Tomlinson D, Harris J. Successful treatment of cryptococcal meningitis with liposomal amphotericin-B after failure of treatment with fluconazole and conventional amphotericin-B. AIDS 5: 231-232, 1991.
12. Gokhale PC, Barapatre RJ, Advani SH, Kshirsagar NA, Pandya SK. Successful treatment of dissiminated candidiasis resistant to amphotericin-B by liposomal amphotericin-B: a case report. J Cancer Res Clin Oncol 119: 569-571, 1993.
13. Krüger WH, Stockschläder M, Rüßmann B, Berger C, Hoffknecht MM, Sobottka I, Kohlschütter B, Kroschke G, Kroger N, Horstmann M, Kabisch H, Zander AR. Experience with liposomal amphotericin-B in 60 patients undergoing high dose therapy and bone marrow or peripheral blood stem cell transplantation. Br J Haematol 91: 684-690, 1995.
14. Pfaller MA, Bale M, Buschelman B, Lancaster M, Espinel-Ingroff A, Rex JH, Rinaldi MG. Selection of candidate quality control isolates and tentative quality control ranges for in vitro susceptibility testing of yeast isolates by national committee for clinical laboratory standards proposed standard methods. J Clin Microbiol 32: 1650-1653, 1994.
15. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation treated prophylactically with Fluconazole. N Engl J Med 325: 1274-1277, 1991.
16. Proffitt RT, Satorius A, Chiang SM, Sullivan L, Adler-Moore JP. Pharmacology and toxicology of a liposomal formulation of amphotericin b (ambisome) in rodents. J Antimicrob Chemother 28 (Suppl B): 49-61, 1991.
17. Tollemar J, Ringden O, Tyden G. Liposomal amphotericin-B (AmBisome) treatment in solid organ and bone marrow transplant recipients. Efficacy and safety evaluation. Clin Transplant 4: 167-195, 1990.
18. Pahls S, Schaffner A. Comparison of the activity of free and liposomal amphotericin b in vitro and in a model of systemic and localized murine candidiasis. J Infect Dis 169: 1057-1061, 1994.